Evidence of the beneficial effects of the American Heart Association ideal cardiovascular health definition among diverse populations is lacking and could have significant public health implications. In the triethnic, community-based, prospective Northern Manhattan Study cohort, 2981 adults Ն40 years of age and free of stroke and myocardial infarction at baseline were followed up for a median of 11 years. We observed a steep gradient relationship between the adjusted hazard ratios for the incidence of myocardial infarction, stroke, or cardiovascular death and the number of ideal health metrics defined by the American Heart Association: 0.73 (95% confidence interval, 0.60 -0.89), 0.61 (95% confidence interval, 0.50 -0.76), 0.49 (95% confidence interval, 0.38 -0.63), and 0.41 (95% confidence interval, 0.26 -0.63) for those having 2, 3, 4, and 5 to 6 ideal health metrics, respectively, compared with those having 0 to 1 ideal health metric (P for trend Ͻ0.0001). Lower cardiovascular death incidence rates were independently associated with a greater number of ideal health behaviors (smoking, physical activity, body mass index, and diet) when controlled for the number of ideal health factors (total cholesterol, blood pressure and glucose). A similar graded relationship was also observed between the number of ideal health metrics and the adjusted incidence rate for myocardial infarction, stroke, and vascular death among whites, blacks, and Caribbean Hispanics. These findings support the application of the AHA ideal cardiovascular health metrics for cardiovascular death risk assessment and health promotion for all Americans regardless of race-ethnic background. The results imply that to lower cardiovascular death risk, environments and policies improving health behaviors are just as important as programs controlling vascular factors. See p 2975.
Remote Monitoring Reduces Healthcare Use and Improves Quality of Care in Heart Failure Patients With Implantable Defibrillators: The Evolution of Management Strategies of Heart Failure Patients With Implantable Defibrillators (EVOLVO) Study
Heart failure patients with implantable defibrillators often visit the hospital for unscheduled examinations, placing a great burden on healthcare providers. Device manufacturers offer a technology for remote defibrillator monitoring with the purpose of allowing physicians to remotely access patients' data and reducing unnecessary routine and interim visits. The Evolution of Management Strategies of Heart Failure Patients With Implantable Defibrillators (EVOLVO) study was a multicenter randomized trial designed to assess whether remote management can reduce emergency healthcare use in heart failure patients implanted with defibrillators endowed with specific diagnostic features compared with standard management consisting of scheduled in-office visits and patient response to audible alerts. Over 16 months, the rate of emergency department or urgent in-office visits for heart failure, arrhythmias, or device-related events decreased by 35% and total healthcare visits were 21% less frequent with remote monitoring. Moreover, with remote monitoring system, the time from an alert condition to review of the data was reduced from 24.8 to 1.4 days, and the change in patients' quality of life was more favorable. These findings may have important implications.
Indeed, our study confirmed that remote management of heart failure patients implanted with defibrillators allows timely notification of potentially critical situations. Moreover, it has the effect of shifting healthcare visits from the emergency department to the clinic and increasing the appropriateness of in-office visits, thereby reducing costs and the burden on the healthcare system. Thus, compared with the standard follow-up through in-office visits and audible alerts, remote monitoring results in increased efficiency for healthcare providers and improved quality of care for patients. See p 2985.
␤-Adrenergic Receptor Stimulation Transactivates Protease-Activated Receptor 1 via Matrix Metalloproteinase 13 in Cardiac Cells
Chronic heart failure of both ischemic and nonischemic etiology is accompanied by chronically elevated circulating plasma catecholamines. Chronic overstimulation of cardiac ␤-adrenergic receptors is known to be a key contributor to the establishment and maintenance of pathological cardiac remodeling. However, the mechanism by which ␤-adrenergic receptor overactivation contributes to heart failure remains poorly understood. Herein, we have discovered that cardiac protease-activated receptor 1 (PAR1) (also known as the thrombin receptor) can be transactivated by ␤-adrenergic receptor overstimulation via the matrix metalloproteinase 13 (MMP-13, also known as collagenase 3). We propose that this mechanism plays a significant role in the establishment of cardiac dysfunction induced by chronic adrenergic overstimulation. This is of particular clinical interest because PAR1 antagonists may therefore not only prevent PAR1 activation by thrombin (in case of an ischemic event) but could in addition antagonize aspects of adrenergic-dependent pathological cardiac remodeling. Our work further suggests that MMP-13-mediated activation of PAR1 can also participate in the establishment of cardiac dysfunction. Therefore, we propose that the MMP-13/PAR1 axis represents an important novel target to treat heart failure. Drugs interfering with this axis are already available. Inhibitors of MMP-13 are currently under evaluation in animal models, primarily as a cure for rheumatoid arthritis and osteoarthritis, in which MMP-13 has been shown to play a pathological role. Moreover, antagonists of PAR1 are now undergoing clinical trials as novel antiplatelet agents. In conclusion, we suggest that MMP-13 inhibitors and PAR1 antagonists may hold therapeutic potential for the treatment of heart failure. See p 2993.
Relationship Between Chest Compression Rates and Outcomes From Cardiac Arrest
Guidelines for cardiopulmonary resuscitation recommend a chest compression rate of at least 100 compressions per minute but do not provide an upper limit for rate because of lack of evidence from human studies with return of spontaneous circulation or survival as outcomes. In this study, we describe chest compression rates used by emergency medical service providers to resuscitate patients with out-of-hospital cardiac arrest, and we sought to determine the relationship between chest compression rate and return of spontaneous circulation and survival. This study used data from the Resuscitation Outcomes Consortium Epidemiological Cardiac Arrest Registry database. The study included Ͼ3000 patients who had out-of-hospital cardiac arrest and cardiopulmonary resuscitation. The investigators found that 75% of rescuers used chest compression rates Ͼ100/min, and one-third used rates Ͼ120/min. Depth of chest compressions is an important factor related to cardiopulmonary resuscitation quality and survival. We found that chest compression depth decreases when chest compression rate is Ͼ140/min. This study found that the likelihood of return of spontaneous circulation from out-of-hospital cardiac arrest was greatest with use of a chest compression rate of Ϸ125 compressions per minute and then declines sharply with faster rates. By using chest compression rates of at least 100/min but no faster than 125/min, we can further improve return of spontaneous circulation. See p 3004.
Simple Score to Assess the Risk of Rejection After Orthotopic Heart Transplantation
In this study, we have derived and validated a risk score for rejection after orthotopic heart transplantation. We used data from the United Network for Organ Sharing registry on Ͼ14 000 orthotopic heart transplantation recipients to achieve this goal. The 13-point risk score incorporated 4 variables (age, race, sex, and HLA matching) and was highly predictive of drug-treated rejection in the first posttransplantation year. Predicted rates of 1-year rejection ranged from 16.2% in those with a score of 0 to 50.7% in those with a score of 13. In weighted regression analysis, there was a strong correlation between these predicted rates based on the derivation cohort and actual, observed rejection rates in the validation cohort (r 2 ϭ0.96, PϽ0.001). Logistic regression analysis also demonstrated this significant association (odds ratio, 1.13; PϽ0.001). The c index for the score was equivalent in the derivation and validation cohorts (cϭ0.67). This highly predictive, simple-to-calculate risk score has potential utility in tailoring immunosuppressive regimens for ortho-topic heart transplantation recipients and in research stratification. See p 3013.
Racial and Ethnic Differences in Wait-List Outcomes in Patients Listed for Heart Transplantation in the United States
Although racial differences in long-term survival after heart transplant are well known, there is limited information regarding racial/ ethnic differences in mortality among those listed for a heart transplant. In this study, the authors compared wait-list and early posttransplant mortality among white, black, and Hispanic adult patients listed in the United States for heart transplant between July 2006 and September 2010. Of 10 377 patients analyzed, 71% were white, 21% were black, and 8% were Hispanic. Black and Hispanic patients were more likely to be listed with higher urgency in comparison with white patients. Overall, 10.5% of white, 11.6% of black, and 13.4% of Hispanic candidates died on the wait-list or became too sick for a transplant (removed from the list because of deterioration) within 1 year of listing. After adjusting for baseline risk factors, Hispanic patients were at 51% higher risk of dying on the wait list or becoming too sick for a transplant in comparison with white patients. Black patients were not at higher risk of dying on the wait-list. Among patients who received a heart transplant, posttransplant in-hospital mortality was 53% higher in black recipients in comparison with white recipients after adjusting for other risk factors at the time of transplant, but posttransplant in-hospital mortality was not different in Hispanic recipients in comparison with white recipients. The authors conclude that these gaps in wait-list and posttransplant outcomes among racial/ethnic groups merit further investigation. See p 3022.
